ArticleACS nano2026
Manganese-Doped Carbon Nanodots as Next-Generation MRI and Fluorescence Imaging Agents.
Article in ACS nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Carbon nanodots (CNDs) have emerged as highly promising nanomaterials for biomedical applications due to their intrinsic fluorescence, excellent biocompatibility, and facile surface functionalization. Doping CNDs with paramagnetic metals, such as manganese (Mn), enables the development of dual-modal imaging probes that integrate magnetic resonance imaging (MRI) and fluorescence imaging (FI). Mn is a particularly attractive alternative to Gd-based contrast agents, offering lower toxicity, favorable paramagnetic properties, and physiological relevance. Here, we report a rapid microwave-assisted hydrothermal synthesis of Mn-doped carbon nanodots (MnCNDs) as dual-mode contrast agents for MRI and FI. A size exclusion chromatography purification step yielded a uniform population of MnCNDs containing 5% (w/w) Mn(II), characterized by excitation-dependent fluorescence emission and an amorphous carbon structure with a metal-enriched core. Importantly, MnCNDs exhibit a stable longitudinal relaxivity over 7 days, comparable to that of clinically used MRI contrast agents. Confocal fluorescence imaging confirmed efficient cellular uptake in vitro, while T1-weighted MRI in mice demonstrated their biocompatibility and strong potential as effective MRI contrast agents for in vivo applications. These findings position MnCNDs as robust and versatile nanoprobes for next-generation, multimodal bioimaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.